1. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. Issue 1 (22nd January 2021) Authors: Rose, April A N; Armstrong, Susan M; Hogg, David; Butler, Marcus O; Saibil, Samuel D; Arteaga, Diana P; Pimentel Muniz, Thiago; Kelly, Deirdre; Ghazarian, Danny; King, Ian; Kamil, Zaid Saeed; Ross, Kendra; Spreafico, Anna Journal: Journal for immunotherapy of cancer Issue: Volume 9:Issue 1(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗